Progenics Pharmaceuticals Inc.'s registrational Phase IIb study of its novel radiotherapeutic Azedra (iobenguane I 131) Injection, has hit its primary endpoint, setting the stage for an FDA filing in the next quarter and opening up a new ultra-orphan market.
The open-label, multi-center study was conducted under a special protocol assessment (SPA) and evaluated Azedra in patients with malignant and/or...